Creon Capsule, Delayed Release Pellets
NDC Package 0032-1206-07

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Creon (pancrelipase) capsules is this medication contains digestive enzymes to help break down and digest fats, starch, and proteins in food. This formulation utilizes a capsule, delayed release pellets delivery system. Marketed by Abbvie Inc., this product is identified by NDC 0032-1206 and is authorized under FDA application BLA020725.

Identification & Billing

NDC Package Code
0032-1206-07
Package Description
250 CAPSULE, DELAYED RELEASE PELLETS in 1 BOTTLE
Product Code
0032-1206
11-Digit Billing Format
00032120607
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
250 EA
RxNorm Crosswalk
  • RxCUI: 1113042 - lipase 3000 UNT / amylase 15,000 UNT / protease 9500 UNT Delayed Release Oral Capsule
  • RxCUI: 1113042 - amylase 15000 UNT / lipase 3000 UNT / protease 9500 UNT Delayed Release Oral Capsule
  • RxCUI: 1113042 - amylase 15,000 UNT / lipase 3000 UNT / protease 9500 UNT Delayed Release Oral Capsule
  • RxCUI: 1113042 - amylases 15,000 UNT / endopeptidases 9500 UNT / lipase 3000 UNT Delayed Release Oral Capsule
  • RxCUI: 1113046 - CREON 3000 UNT / 15,000 UNT / 9500 UNT Delayed Release Oral Capsule

Clinical Specifications

Proprietary Name
Creon
Non-Proprietary Name
Pancrelipase
Substance Name
Pancrelipase Amylase; Pancrelipase Lipase; Pancrelipase Protease
Dosage Form
Capsule, Delayed Release Pellets - A solid dosage form in which the drug is enclosed within either a hard or soft soluble container or "shell" made from a suitable form of gelatin; the drug itself is in the form of granules to which enteric coating has been applied, thus delaying release of the drug until its passage into the intestines.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
This medication contains digestive enzymes to help break down and digest fats, starch, and proteins in food. It is used in conditions where the pancreas cannot make or does not release enough digestive enzymes into the small intestines to digest the food (conditions such as chronic pancreatitis, cystic fibrosis, cancer of the pancreas, post-pancreatectomy, post-gastrointestinal bypass surgery).

Regulatory & Marketing

Labeler Name
Abbvie Inc.
Product Type
Human Prescription Drug
FDA Application #
BLA020725
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
04-30-2009
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (0032-1206). Click a package code to view its specific billing and regulatory data.

0032-1206-01
1 BOTTLE in 1 CARTON / 100 CAPSULE, DELAYED RELEASE PELLETS in 1 BOTTLE
0032-1206-56
1 BOTTLE in 1 CARTON / 100 CAPSULE, DELAYED RELEASE PELLETS in 1 BOTTLE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0032-1206-07 identifies a specific commercial package of 250 capsule, delayed release pellets in 1 bottle of Creon, a human prescription drug labeled by Abbvie Inc.. This capsule, delayed release pellets is formulated for oral use and contains pancrelipase amylase; pancrelipase lipase; pancrelipase protease as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Abbvie Inc. on April 30, 2009. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

This medication contains digestive enzymes to help break down and digest fats, starch, and proteins in food. It is used in conditions where the pancreas cannot make or does not release enough digestive enzymes into the small intestines to digest the food (conditions such as chronic pancreatitis, cystic fibrosis, cancer of the pancreas, post-pancreatectomy, post-gastrointestinal bypass surgery).

How is this Abbvie Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00032120607. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 250 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0032-1206-07
11-Digit CMS (5-4-2)
00032-1206-07

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.